Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non‐medullary thyroid cancer

PURPOSE: Non-medullary thyroid cancer (NMTC) treatment is based on the ability of thyroid follicular cells to accumulate radioactive iodide (RAI). However, in a subset of NMTC patients tumor dedifferentiation occurs, leading to RAI resistance. Digoxin has been demonstrated to restore iodide uptake c...

Descripción completa

Detalles Bibliográficos
Autores principales: Crezee, Thomas, Tesselaar, Marika H., Nagarajah, James, Corver, Willem E., Morreau, Johannes, Pritchard, Catrin, Kimura, Shioko, Kuiper, Josephina G., van Engen-van Grunsven, Ilse, Smit, Jan W. A., Netea-Maier, Romana T., Plantinga, Theo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213564/
https://www.ncbi.nlm.nih.gov/pubmed/33534128
http://dx.doi.org/10.1007/s13402-021-00588-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213564/
https://www.ncbi.nlm.nih.gov/pubmed/33534128
http://dx.doi.org/10.1007/s13402-021-00588-y

Ejemplares similares